Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human papillomavirus vaccine recombinant quadrivalent - Serum Institute of India

Next Previous
X
Search
Drug Profile

Human papillomavirus vaccine recombinant quadrivalent - Serum Institute of India

Alternative Names: CERVAVAC; Human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine - Serum Institute of India; Human papillomavirus (types 6, 11, 16, 18) L1 VLP vaccine - Serum Institute of India; Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine - Serum Institute of India; qHPV vaccine - Serum Institute of India; Recombinant quadrivalent HPV vaccine - Serum Institute Of India; SIIPL qHPV vaccine; Tetravalent HPV vaccine - Serum Institute of India

Latest Information Update: 12 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Serum Institute of India
  • Developer Bill & Melinda Gates Foundation; Biotechnology Industry Research Assistance Council; Department of Biotechnology (India); Serum Institute of India
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cervical cancer

Most Recent Events

  • 04 Mar 2024 Serum Institute of India plans a phase III trial for Human papillomavirus infection (Prevention) in Kenya, Mozambique and South Africa in June 2024 (NCT06281119)
  • 24 Jan 2023 Launched for Cervical cancer (Prevention) in India (IM)
  • 01 Sep 2022 The Serum Institute Of India (SII) enters into a partnership agreement with Department of Biotechnology (DBT) and Bill and Melinda Gates Foundation for the development of Human papillomavirus vaccine recombinant quadrivalent, prior to September 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top